ALX-1 is under clinical development by Vast Therapeutics and currently in Phase I for Bronchiectasis. According to GlobalData, Phase I drugs for Bronchiectasis have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALX-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALX-1 overview
BIOC-11 is under development for the treatment of bronchiectasis caused by Pseudomonas aeruginosa and cystic fibrosis. This candidate is formulated as an isotonic, buffered aqueous solution for oral inhalation through a nebulizer. It is being developed based on nitric oxide-releasing biopolymer platform.
It was under development for the treatment of non tuberculous mycobacterial lung disease and chronic pulmonary infections due to Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Vast Therapeutics overview
Vast Therapeutics is a clinical-stage life science company. It focuses on breaking the debilitating cycle of chronic infection and inflammation in respiratory diseases. The company is developing an ALX1 drug candidate that contains a water-soluble, small-molecule prodrug that releases the active metabolite nitric oxide (NO). Vast Therapeutics’ pipeline include therapies for cystic fibrosis, non-cystic fibrosis bronchiectasis, nontuberculous mycobacteria (NTM), and chronic obstructive pulmonary disease. The company is also developing other nitric oxide prodrugs in inhaled form. Its platform stabilizes nitric oxide, delivers through inhalation, and releases it to the patient’s lungs targeting the most needed area. Vast Therapeutics is headquartered in Morrisville, North Carolina, the US.
For a complete picture of ALX-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
